Menu
  • Plenary Session II: Thursday, October 22, 2020

    Defining the New CF in the Era of Highly Effective Modulators

    Speaker: Jennifer L. Taylor-Cousar, M.D., MSCS, ATS

    In this session, the latest research into highly effective CFTR modulators will be highlighted, providing and in-depth overview of the CFTR modulator research landscape one-year post-approval of Trikafta. The speaker will describe the ongoing and upcoming studies looking at the holistic impact of highly effective CFTR modulation on the lives of people with CF. Finally, there will be a review of on-going and upcoming studies for the development of new modulators as well as the potential impact of modulators on complications.

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research
  • Plenary III: Friday, October 23, 2020

    Advancing GI Frontier for People with CF

    Speaker: Steven D. Freedman, M.D., Ph.D.

    In this session, Dr. Freedman walks us through the gastrointestinal aspects of CF, focusing on intestinal, liver, and pancreatic disease and the exciting new directions in GI as part of specialized CF care. Research initiatives and advances in developing a GI workforce through the CF Foundation's DIGEST program will be highlighted.

    Topics: Treatment, CF Complications, Plenary, Clinical Research
  • Plenary Session I: Thursday, October 18, 2018

    "Improving Outcomes of Infections in the Age of CFTR Modulators"

    Speaker: Lisa Saiman, M.D., M.P.H.

    In this session, Dr. Lisa Saiman will address the challenges of infections in people with CF and discuss why infections remain a major focus of the CF community, even in the era of effective CFTR modulators. She will provide an overview of CF infections, describe ongoing studies to increase our understanding of CF microorganisms and their optimal treatment, and discuss current strategies to develop new anti-infective agents to treat even the most difficult infections.

     

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research
  • Plenary Session II: Friday, October 19, 2018

    "Anti-inflammatories & Mucociliary Clearance Therapies in the Age of CFTR Modulators"

    Speaker: Felix Ratjen, M.D., Ph.D.

    This plenary will review the effect of CFTR dysfunction and CFTR restoration on both inflammation and mucociliary clearance in individuals with CF. Current and future therapeutic strategies to address inflammation and mucociliary clearance will be discussed, as well as how these strategies have potential to benefit both those patients using CFTR modulators and those not eligible for modulators.

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research
  • Plenary Session III: Saturday, October 20, 2018

    "Partnering: The Oldest New Idea to Improve CF Care"

    Speakers: Maren Batalden, M.D., Kathryn Sabadosa, M.P.H., Melanie Abdelnour, Cynthia George, R.N., M.S.N., F.N.P.

    Central to the management of cystic fibrosis are the relationships that people with CF and their families build with their clinical care teams. As people with CF live longer, their disease increases in complexity, making coordination and individualized care ever more dependent upon these foundational relationships. Actively partnering in health care is a learning process and although, highly regarded, realizing and maintaining full partnership can be challenging. This plenary will walk through the evolution of partnering, specifically in CF care and more broadly in the context of health care and society, further thinking by exploring the tensions impacting partnership, and highlight new strategies supported by the CF Foundation, so that all people living with CF can better balance their daily care while attaining personal goals. The plenary will end with a panel discussion between an adult living with CF, a parent, and a healthcare professional from the CF Foundation.

    Topics: Health Outcomes, Treatment, Care Model, Observational Research, Plenary
  • Plenary Session I: Thursday, November 2, 2017

    "Matching Medicines With Mutations"

    Speakers:   Michael P. Boyle, M.D., FCCP and Philip J. Thomas, Ph.D.

    Increasing numbers of people with CF now benefit from disease-altering small molecule therapies that target the basic defect in CFTR.  Use of these therapies has been extended recently using a combination of in vitro laboratory experiments to identify responsive mutations, and clinical trials to determine effect on clinical outcomes. This plenary will summarize how recent advances may allow in the near future over 90% of individuals with CF to benefit from therapies that target the basic defect in CFTR, including even those with the rarest disease causing mutations.

    Topics: Health Outcomes, Treatment, CFTR, Plenary, Clinical Research, Drug Development Pipeline
Showing 1–6 of 8 results